Why we don’t (not really) think properly about risk in drug development

Written By Johnathan Lowery

Patient Safety, Regulatory Compliance and Well-Formulated Studies are “the job” and have already been priced in.

Coming Soon

Johnathan Lowery
Previous

Quantifying the value of investment in innovation for clinical development
Next

Drug development is not like software development (and why this matters)